Not 3 weeks after taking Humacyte public, Rajiv Shukla launches another blank-check company - Endpoints News

kosongkosonig.blogspot.com

Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion and adding a slate of new cancer drugs to the pipeline.

Amgen is paying $38 a share, putting the deal value at $1.9 billion. The stock closed at $21.26 last night, giving investors a 78% premium.

The jewel in the crown of this deal is bemarituzumab, which Amgen describes as a first-in-class, Phase III-ready anti-FGFR2b antibody. Amgen was drawn to the bargaining table by Five Prime’s mid-stage data on gastric cancer, satisfied by PFS and OS data helping to validate FGFR2b as a target. Amgen researchers will now expand on the R&D program in other epithelial cancers, including lung, breast, ovarian and other cancers.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,800+ biopharma pros reading Endpoints daily — and it's free.

Let's block ads! (Why?)

"blank" - Google News
March 05, 2021 at 01:15PM
https://ift.tt/3kRmOBg

Not 3 weeks after taking Humacyte public, Rajiv Shukla launches another blank-check company - Endpoints News
"blank" - Google News
https://ift.tt/3aXU3fw
https://ift.tt/2Wij67R

Bagikan Berita Ini